Statistical optimization and validation of a novel ultra-performance liquid chromatography method for estimation of nintedanib in rat and human plasma

Author:

Shukla Snehal K1,Kadry Hossam2,Bhatt Jayshil A3,Elbatanony Rasha14,Ahsan Fakhrul2,Gupta Vivek1

Affiliation:

1. Department of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, St. John's University, Queens, NY 11432, USA

2. School of Pharmacy, Texas Tech University Health Sciences Center, 1300 S Coulter, Amarillo, TX 79106, USA

3. Arnold & Marie Schwartz College of Pharmacy, Long Island University, 75 Dekalb Ave L130, Brooklyn, NY 11201, USA

4. Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences & Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt

Abstract

Aim: A high throughput ultra-performance liquid chromatography (UPLC)-ultraviolet method for quantification of nintedanib in rat and human plasma was developed and optimized using chemometrical approach. Method: Design of experiment and multivariate statistical approach was used for definition of optimized method. Final separation was performed using protein precipitation method on ACQUITY HSS T3 C18 column in isocratic mode using potassium phosphate buffer (pH 7.5): acetonitrile. Results: Method was validated as per US-FDA guidelines linearly from 15–750 ng/ml. All quality control samples showed <15% relative standard deviation for precision and 85–115% accuracy along with >98% extraction recovery. Conclusion: The developed method is easily applicable in determining pharmacokinetic parameters in preclinical subjects along with successful implementation for quantification in human plasma samples.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Reference27 articles.

1. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

2. Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?

3. Nintedanib-cyclodextrin complex to improve bio-activity and intestinal permeability

4. Nintedanib: First Global Approval

5. Boehringer Ingelheim. Vargatef® (nintedanib) approved in the EU for NSCLC (2014). https://www.boehringer-ingelheim.pt/press-release/vargatefr-nintedanib-approved-eu-nsclc

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3